Mural Oncology Net Worth

Mural Oncology Net Worth Breakdown

  MURA
The net worth of Mural Oncology plc is the difference between its total assets and liabilities. Mural Oncology's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Mural Oncology's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Mural Oncology's net worth can be used as a measure of its financial health and stability which can help investors to decide if Mural Oncology is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Mural Oncology plc stock.

Mural Oncology Net Worth Analysis

Mural Oncology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mural Oncology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mural Oncology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mural Oncology's net worth analysis. One common approach is to calculate Mural Oncology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mural Oncology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mural Oncology's net worth. This approach calculates the present value of Mural Oncology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mural Oncology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mural Oncology's net worth. This involves comparing Mural Oncology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mural Oncology's net worth relative to its peers.

Enterprise Value

(171.57 Million)

To determine if Mural Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mural Oncology's net worth research are outlined below:
Mural Oncology plc had very high historical volatility over the last 90 days
Mural Oncology plc has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (207.45 M) with profit before overhead, payroll, taxes, and interest of 0.
Mural Oncology generates negative cash flow from operations
Mural Oncology plc has a poor financial position based on the latest SEC disclosures
About 69.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Disposition of 2555 shares by Keson-brookes Maiken of Mural Oncology at 3.27 subject to Rule 16b-3
Mural Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mural Oncology plc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mural Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
14th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Mural Oncology Target Price Consensus

Mural target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Mural Oncology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
   3  Strong Buy
Most Mural analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Mural stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Mural Oncology plc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Mural Oncology Target Price Projection

Mural Oncology's current and average target prices are 3.47 and 16.33, respectively. The current price of Mural Oncology is the price at which Mural Oncology plc is currently trading. On the other hand, Mural Oncology's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Mural Oncology Market Quote on 8th of January 2025

Low Price3.36Odds
High Price3.54Odds

3.47

Target Price

Analyst Consensus On Mural Oncology Target Price

Low Estimate14.86Odds
High Estimate18.13Odds

16.3333

Historical Lowest Forecast  14.86 Target Price  16.33 Highest Forecast  18.13
Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Mural Oncology plc and the information provided on this page.

Follow Mural Oncology's market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 58.69 M.

Market Cap

60.17 Million

Project Mural Oncology's profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.62)(0.65)
Return On Capital Employed(0.64)(0.67)
Return On Assets(0.62)(0.65)
Return On Equity(0.90)(0.86)
When accessing Mural Oncology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mural Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mural Oncology's profitability and make more informed investment decisions.
Please note, the presentation of Mural Oncology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mural Oncology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mural Oncology's management manipulating its earnings.

Evaluate Mural Oncology's management efficiency

Mural Oncology plc has return on total asset (ROA) of (0.8105) % which means that it has lost $0.8105 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7834) %, meaning that it created substantial loss on money invested by shareholders. Mural Oncology's management efficiency ratios could be used to measure how well Mural Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of January 8, 2025, Return On Tangible Assets is expected to decline to -0.65. In addition to that, Return On Capital Employed is expected to decline to -0.67. At present, Mural Oncology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 22.5 M, whereas Other Current Assets are forecasted to decline to about 801.1 K.
Last ReportedProjected for Next Year
Book Value Per Share 14.23  14.94 
Tangible Book Value Per Share 14.23  14.94 
Enterprise Value Over EBITDA 0.73  0.77 
Price Book Value Ratio 0.34  0.35 
Enterprise Value Multiple 0.73  0.77 
Price Fair Value 0.34  0.35 
Enterprise Value-180.6 M-171.6 M
The strategic initiatives led by Mural Oncology's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Equity
(1.78)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mural Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mural Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mural Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Mural Oncology Corporate Filings

F4
26th of December 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
14th of November 2024
Other Reports
ViewVerify
8K
13th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
12th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
Mural Oncology time-series forecasting models is one of many Mural Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mural Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Mural Oncology Earnings per Share Projection vs Actual

Mural Oncology Corporate Executives

Elected by the shareholders, the Mural Oncology's board of directors comprises two types of representatives: Mural Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mural. The board's role is to monitor Mural Oncology's management team and ensure that shareholders' interests are well served. Mural Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mural Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Adam BAPrincipal CFOProfile
When determining whether Mural Oncology plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mural Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mural Oncology Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mural Oncology Plc Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mural Oncology plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mural Oncology. If investors know Mural will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mural Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.02)
Return On Assets
(0.81)
Return On Equity
(1.78)
The market value of Mural Oncology plc is measured differently than its book value, which is the value of Mural that is recorded on the company's balance sheet. Investors also form their own opinion of Mural Oncology's value that differs from its market value or its book value, called intrinsic value, which is Mural Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mural Oncology's market value can be influenced by many factors that don't directly affect Mural Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mural Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mural Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mural Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.